On-line CE-LIF-MS technology for the direct characterization of N-linked glycans from therapeutic antibodies.
about
In vitro and in vivo modifications of recombinant and human IgG antibodiesGlycan analysis of therapeutic glycoproteinsRapid release of N-linked glycans from glycoproteins by pressure-cycling technologyTandem laser-induced fluorescence and mass spectrometry detection for high-performance liquid chromatography analysis of the in vitro metabolism of doxorubicin.Capillary electrophoresis-mass spectrometry of carbohydrates.Highly sensitive capillary electrophoresis analysis of N-linked oligosaccharides in glycoproteins following fluorescence derivatization with rhodamine 110 and laser-induced fluorescence detection.Alignment of laser-induced fluorescence and mass spectrometric detection traces using electrophoretic mobility scaling in CE-LIF-MS of labeled N-glycans.Structural glycomic analyses at high sensitivity: a decade of progressAnalysis of native and APTS-labeled N-glycans by capillary electrophoresis/time-of-flight mass spectrometry.Mass spectrometry and glycomicsComparative glycoprofiling of HIV gp120 immunogens by capillary electrophoresis and MALDI mass spectrometry.N-Glycan profiling of dried blood spotsCharacterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS.Analysis of glycans derived from glycoconjugates by capillary electrophoresis-mass spectrometry.Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles--part 1: separation-based methodsAnalytical glycobiology at high sensitivity: current approaches and directionsQuantitative glycomics strategiesBioanalytical tools for the discovery of eukaryotic glycoproteins applied to the analysis of bacterial glycoproteins.Glycome profiling using modern glycomics technology: technical aspects and applications.Glycan labeling strategies and their use in identification and quantification.High-sensitivity analytical approaches for the structural characterization of glycoproteins.Analysis of glycoforms on the glycosylation site and the glycans in monoclonal antibody biopharmaceuticals.Capillary electrophoresis/mass spectrometry relevant to pharmaceutical and biotechnological applications.Capillary electrophoresis-mass spectrometry for analysis of complex samples.Glycosylation: impact, control and improvement during therapeutic protein production.Applications of capillary electrophoresis in characterizing recombinant protein therapeutics.Effects of copper on CHO cells: cellular requirements and product quality considerations.Quality control and stability studies with the monoclonal antibody, trastuzumab: application of 1D- vs. 2D-gel electrophoresis.Chemoenzymatic Assembly of Bacterial Glycoconjugates for Site-Specific Orthogonal Labeling.Advanced microscale bioreactor system: a representative scale-down model for bench-top bioreactors.Kinetics of N-Glycan Release from Human Immunoglobulin G (IgG) by PNGase F: All Glycans Are Not Created Equal.Improved sample preparation method for glycan analysis of glycoproteins by CE-LIF and CE-MS.In-line SPE-CE using a fritless bead string design--application for the analysis of organic sulfonates including inline SPE-CE-MS for APTS-labeled glycans.Mass spectrometry for protein sialoglycosylation.Microfluidic Capillary Electrophoresis-Mass Spectrometry for Analysis of Monosaccharides, Oligosaccharides, and Glycopeptides.Comparative core fucosylation analysis of some major therapeutic antibody N-glycans by direct infusion ESI-MS and CE-LIF detection.Enzymatic removal of N-glycans by PNGase F coated magnetic microparticles.Quantitative twoplex glycan analysis using 12C6 and 13C6 stable isotope 2-aminobenzoic acid labelling and capillary electrophoresis mass spectrometry.
P2860
Q26859713-32662E5D-C66B-4A6B-82CF-FBD82B8399E6Q28082842-77A847EC-AD44-46DC-BFB6-306335314A0CQ33532738-89483F22-8413-4323-9C8F-01D6CBB5E40FQ33687552-8A73C0A7-F66E-4C26-87D1-7EEFB775BCE1Q33939419-31669C5A-2081-4CED-A9FA-6FFE3061CD4CQ34105021-0E3C3B94-0A1B-4D39-8574-22E2F2C6629DQ34208580-75E7650E-59EC-4183-AE07-C8B7F781F615Q34656853-1F3A7B4A-6DFB-424B-A52F-20C672C1E7CEQ34891439-AA1344DE-15A2-45FC-B74C-1223DAD8791BQ35097817-279BF24D-63A2-4E99-A973-6C50811CAE7BQ35586908-2E11C505-7B3B-45CC-BD47-EB6DCA60547BQ35675417-1BFBD8F0-77B3-4230-9E97-90177312CBFCQ35975965-C71D8A21-FA9D-497D-A423-AF8A93CE7A7FQ35988418-EEAE1222-05F2-4FFD-B452-8A8F6E218369Q36216323-CD5E4253-A7DC-4E19-A023-F3D2DB8FADA7Q36651493-61C3302F-6545-4663-AD9F-96C68B683895Q36742414-9DACA6B2-B9C9-4321-BC7B-8A5120A2DE07Q37390672-FBDCEE6F-4DB5-44F7-8DEA-57D1A6E63999Q37686527-43BD3D4F-FA90-478B-8C55-FD04F2B1B2DEQ37708129-4064CA85-D709-4235-AD40-BFA94B45D639Q37712517-9D8F456D-04FB-4CCA-B1E8-9E01A7389A5CQ37972871-EB1411AC-C1AF-4707-AA65-E700D53BCF7CQ38021959-04F6CC40-98B1-4E2B-A33B-607E0A7FA140Q38034210-A858BEFB-3EEE-4445-8D01-C4AB052A6C30Q38126913-697A049A-8574-4ED1-97DC-9CBC8FC64211Q38152378-3574C560-ABCA-4321-BBF3-E086504D3531Q38948246-AE2691CC-8B31-4264-AF72-8830BD2DDA42Q39357941-D807AD55-19B2-4009-B971-536BBF604B08Q41059924-AA4A34DA-AE84-410C-A725-0E5F335232F8Q41513843-22273372-9D73-43DB-840D-37391CEEE0AAQ42372965-0B7F4743-445D-412D-84D7-977FFCD733E7Q42737026-FC0957B1-5FC1-4EBC-A926-1748152BE955Q43671273-F3C6BE96-9D6B-4A92-8ED6-157F99F91824Q46243684-4146CB77-BA05-4B98-88E3-7CF46F0AB6E3Q48116778-15C74F11-BE13-4083-80AA-04A945588621Q50878059-E0889DC3-8471-4EE4-AEA6-AAE072E2A914Q51526563-67682EC7-15C4-4F8F-A74C-C4C39C54D11BQ54503422-52547BF0-A27C-4769-864C-C181BC42820A
P2860
On-line CE-LIF-MS technology for the direct characterization of N-linked glycans from therapeutic antibodies.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
On-line CE-LIF-MS technology f ...... s from therapeutic antibodies.
@ast
On-line CE-LIF-MS technology f ...... s from therapeutic antibodies.
@en
On-line CE-LIF-MS technology f ...... s from therapeutic antibodies.
@nl
type
label
On-line CE-LIF-MS technology f ...... s from therapeutic antibodies.
@ast
On-line CE-LIF-MS technology f ...... s from therapeutic antibodies.
@en
On-line CE-LIF-MS technology f ...... s from therapeutic antibodies.
@nl
prefLabel
On-line CE-LIF-MS technology f ...... s from therapeutic antibodies.
@ast
On-line CE-LIF-MS technology f ...... s from therapeutic antibodies.
@en
On-line CE-LIF-MS technology f ...... s from therapeutic antibodies.
@nl
P356
P1433
P1476
On-line CE-LIF-MS technology f ...... s from therapeutic antibodies.
@en
P2093
Lynn A Gennaro
Oscar Salas-Solano
P304
P356
10.1021/AC800152H
P407
P577
2008-04-22T00:00:00Z